Shares of Amsurg Corp. (NASDAQ:AMSG) were down 3.5% during trading on Wednesday . The stock traded as low as $61.20 and last traded at $61.99, with a volume of 1,043,807 shares traded. The stock had previously closed at $64.25.

AMSG has been the topic of several research reports. Mizuho boosted their price target on shares of Amsurg Corp. from $84.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, May 4th. Jefferies Group reissued a “buy” rating and issued a $96.00 price target on shares of Amsurg Corp. in a research report on Thursday, May 5th. Robert W. Baird reissued a “buy” rating on shares of Amsurg Corp. in a research report on Monday, May 16th. Barclays PLC initiated coverage on shares of Amsurg Corp. in a research report on Wednesday, June 1st. They issued an “equal weight” rating and a $85.00 price target on the stock. Finally, Wells Fargo & Co. initiated coverage on shares of Amsurg Corp. in a research report on Tuesday, June 14th. They issued a “market perform” rating on the stock. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $93.91.

The company has a market capitalization of $3.45 billion and a price-to-earnings ratio of 19.037. The company has a 50-day moving average price of $73.81 and a 200-day moving average price of $74.25.

Amsurg Corp. (NASDAQ:AMSG) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.02. The company had revenue of $758.50 million for the quarter, compared to analysts’ expectations of $769.88 million. The business’s revenue was up 21.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.97 EPS. Equities analysts expect that Amsurg Corp. will post $4.33 earnings per share for the current year.

Other institutional investors have bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in Amsurg Corp. by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,994,029 shares of the company’s stock worth $227,552,000 after buying an additional 92,088 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Amsurg Corp. by 1,872.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 194,790 shares of the company’s stock worth $14,804,000 after buying an additional 184,912 shares during the last quarter. Morgan Stanley increased its position in Amsurg Corp. by 115.7% in the fourth quarter. Morgan Stanley now owns 182,105 shares of the company’s stock worth $13,840,000 after buying an additional 97,682 shares during the last quarter. Redwood Investments LLC increased its position in Amsurg Corp. by 20.3% in the fourth quarter. Redwood Investments LLC now owns 28,011 shares of the company’s stock worth $2,129,000 after buying an additional 4,732 shares during the last quarter. Finally, US Bancorp DE increased its position in Amsurg Corp. by 30.5% in the fourth quarter. US Bancorp DE now owns 23,339 shares of the company’s stock worth $1,774,000 after buying an additional 5,461 shares during the last quarter.

AmSurg Corp. is a surgical center and physician services company. The Company is an owner and operator of ambulatory surgery centers (ASCs) in the United States. The Company is also a provider of outsourced physician services in the areas of anesthesiology, children’s services, emergency medicine and radiology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.